Clinical Trials Browser

Interventional × Pancreatic Ductal Adenocarcinoma × 1 year × Clear all

NCT05257993 2026-04-13

Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

Phase 1/2 Recruiting

Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT05846516 2026-04-01

A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT07324096 2026-03-27

AI-PACED

Phase NA Recruiting

Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT04975217 2026-03-20

Fecal Microbial Transplants for the Treatment of Pancreatic Cancer

Phase EARLY_PHASE1 Recruiting

Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT07024615 2026-03-13

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

Phase 1 Recruiting

Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT07199764 2026-03-06

IGNITE

Phase 2 Recruiting

Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT06528093 2026-02-03

A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy

Phase 1 Terminated

Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT05634720 2026-01-26

Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer

Phase 4 Active not recruiting

Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT06574620 2026-01-16

ACCELERATE

Phase NA Recruiting

Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT03851237 2025-12-23

CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy

Phase 1 Completed

Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT05289830 2025-12-10

Escitalopram to Placebo in Patients With Localized Pancreatic Cancer

Phase 2 Terminated

4 enrolled 10 charts

Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT05209074 2025-09-05

Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT03592888 2025-06-29

DC Vaccine in Pancreatic Cancer

Phase 1 Completed

Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT03374852 2025-04-29

CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Ductal Adenocarcinoma